Literature DB >> 30397059

Pharmacodynamics of Minocycline against Acinetobacter baumannii in a Rat Pneumonia Model.

Ziad Tarazi1, Mojgan Sabet1, Michael N Dudley1, David C Griffith2.   

Abstract

Minocycline is currently approved in the United States for the treatment of infections caused by susceptible isolates of Acinetobacter spp. The objective of these studies was to determine the minocycline exposures associated with an antibacterial effect against Acinetobacter baumannii in a rat pneumonia model. Rats received minocycline doses as 30-min intravenous infusions. In the rat pneumonia model, six clinical isolates of A. baumannii with MICs ranging from 0.03 to 4 mg/liter were studied. In this model, minocycline produced a bacteriostatic effect with a free 24-h area under the concentration-time curve (AUC)/MIC ratio of 10 to 16 and produced 1 log of bacterial killing with a free 24-h AUC/MIC of 13 to 24. These exposures can be achieved with the current FDA-approved dosage regimens of intravenous minocycline.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  Acinetobacter baumanniizzm321990; minocycline; pneumonia

Mesh：

Substances：

Year:  2019        PMID： 30397059      PMCID： PMC6355566          DOI： 10.1128/AAC.01671-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  20 in total

1.  Susceptibility of acinetobacter strains isolated from deployed U.S. military personnel.

Authors:  Joshua S Hawley; Clinton K Murray; Matthew E Griffith; M Leticia McElmeel; Letitia C Fulcher; Duane R Hospenthal; James H Jorgensen
Journal:  Antimicrob Agents Chemother       Date:  2006-10-16       Impact factor: 5.191

2.  Pharmacokinetic studies on minocycline in man.

Authors:  H Macdonald; R G Kelly; E S Allen; J F Noble; L A Kanegis
Journal:  Clin Pharmacol Ther       Date:  1973 Sep-Oct       Impact factor: 6.875

3.  Effect of medium type, age and aeration on the MICs of tigecycline and classical tetracyclines.

Authors:  R Hope; M Warner; S Mushtaq; M E Ward; T Parsons; D M Livermore
Journal:  J Antimicrob Chemother       Date:  2005-11-12       Impact factor: 5.790

4.  Update on Acinetobacter species: mechanisms of antimicrobial resistance and contemporary in vitro activity of minocycline and other treatment options.

Authors:  Mariana Castanheira; Rodrigo E Mendes; Ronald N Jones
Journal:  Clin Infect Dis       Date:  2014-12-01       Impact factor: 9.079

Review 5.  A review of intravenous minocycline for treatment of multidrug-resistant Acinetobacter infections.

Authors:  David J Ritchie; Alexandria Garavaglia-Wilson
Journal:  Clin Infect Dis       Date:  2014-12-01       Impact factor: 9.079

6.  Pharmacokinetics of minocycline in renal failure.

Authors:  P G Welling; W R Shaw; S J Uman; F L Tse; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  1975-11       Impact factor: 5.191

7.  In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii.

Authors:  Marc H Scheetz; Chao Qi; John R Warren; Michael J Postelnick; Teresa Zembower; Arlene Obias; Gary A Noskin
Journal:  Antimicrob Agents Chemother       Date:  2007-02-16       Impact factor: 5.191

8.  In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004).

Authors:  Daryl J Hoban; Samuel K Bouchillon; Brian M Johnson; Jack L Johnson; Michael J Dowzicky
Journal:  Diagn Microbiol Infect Dis       Date:  2005-07       Impact factor: 2.803

Review 9.  Acinetobacter baumannii: emergence of a successful pathogen.

Authors:  Anton Y Peleg; Harald Seifert; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

10.  Global in vitro activity of tigecycline and comparator agents: Tigecycline Evaluation and Surveillance Trial 2004-2013.

Authors:  Daryl J Hoban; Ralf Rene Reinert; Samuel K Bouchillon; Michael J Dowzicky
Journal:  Ann Clin Microbiol Antimicrob       Date:  2015-05-10       Impact factor: 3.944
View more
  3 in total

Review 1.  Intravenous Minocycline: A Review in Acinetobacter Infections.

Authors:  Sarah L Greig; Lesley J Scott
Journal:  Drugs       Date:  2016-10       Impact factor: 9.546

2.  Pharmacokinetic and Pharmacodynamic Profiling of Minocycline for Injection following a Single Infusion in Critically Ill Adults in a Phase IV Open-Label Multicenter Study (ACUMIN).

Authors:  Thomas P Lodise; Scott Van Wart; Zoe M Sund; Adam M Bressler; Akram Khan; Amy T Makley; Yasir Hamad; Robert A Salata; Fernanda P Silveira; Matthew D Sims; Badih A Kabchi; Mohamed A Saad; Carrie Brown; Randolph E Oler; Vance Fowler; Richard G Wunderink
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

3.  Metformin reverse minocycline to inhibit minocycline-resistant Acinetobacter baumannii by destroy the outer membrane and enhance membrane potential in vitro.

Authors:  Tingting Guo; Xiaoli Sun; Jie Yang; Liying Yang; Mengying Li; Yuhang Wang; Hongmei Jiao; Guocai Li
Journal:  BMC Microbiol       Date:  2022-09-12       Impact factor: 4.465
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.